当前位置： SCI文献检索 > PROSTATE CANCER AND PROSTATIC DISEASES期刊下所有文献 > Characterization of prostate neuroendocrine cancers and therapeutic management: a literature review.

Characterization of prostate neuroendocrine cancers and therapeutic management: a literature review.

Abstract：

OBJECTIVES:Neuroendocrine prostate cancers (NEPCs) are rare. The current lack of consensus for clinical, biological and pathological characterization as well as therapeutic approach makes the management of those tumors a clinical challenge. This literature review aims to summarize available data on the characterization and management of patients with prostate cancer with a neuroendocrine element. We try to identify major controversies and uncertainties in order to understand all aspects of this particular entity. METHODS:We searched for all articles published and registered in the MEDLINE database before 31 November 2013 with the following search terms: (('prostatic neoplasms' (MeSH Terms)) AND ('carcinoma, neuroendocrine' (MeSH Terms)) OR ('carcinoma, small cell' (MeSH Terms))) AND (English (Language)). RESULTS:Case reports, letters or comments were excluded. We then selected relevant articles from titles and abstracts. Overall, 278 articles published between 1976 and November 2013 were identified. No definition of NEPC seems to be clearly established. Natural history of the disease reveals poor prognosis with median survival of up to 10 to 13 months. Histological characterization appears difficult. Serum markers could be helpful with some controversies in terms of prognostic significance. Concerning management, the majority of patients received local treatment combined with chemotherapy in case of early and localized disease. Few clinical trials described strategy for metastatic disease. CONCLUSIONS:The exploration of the different pathways implicated in the neuroendocrine differentiation of prostate cancers is essential for the comprehension of castration-resistance mechanisms. It will enable the identification of optimal therapeutic strategies for which no recommendation is currently established. Inclusion in prospective clinical trials appears necessary to identify the adequate strategy.

journal_name

Prostate Cancer Prostatic Dis

journal_title

Prostate cancer and prostatic diseases

authors

Sargos P,Ferretti L,Gross-Goupil M,Orre M,Cornelis F,Henriques de Figueiredo B,Houédé N,Merino C,Roubaud G,Dallaudiére B,Richaud P,Fléchon A

doi

10.1038/pcan.2014.17

subject

Has Abstract

pub_date

2014-09-01 00:00:00

pages

220-6

issue

3

eissn

1365-7852

issn

1476-5608

pii

pcan201417

journal_volume

17

pub_type

杂志文章,meta分析,评审

相关文献

PROSTATE CANCER AND PROSTATIC DISEASES文献大全
  • A review of pomegranate in prostate cancer.

    abstract：BACKGROUND:Preclinical studies showing that pomegranate juice and its components inhibit prostate cancer led to multiple clinical trials to determine whether pomegranate products could slow the growth of prostate cancer. This review summarizes the preclinical data and discusses the results of the clinical trials. METH...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章,评审

    doi：10.1038/pcan.2017.19

    authors： Paller CJ,Pantuck A,Carducci MA

    更新日期：2017-09-01 00:00:00

  • End-of-radiation PSA as a novel prognostic factor in patients undergoing definitive radiation and androgen deprivation therapy for prostate cancer.

    abstract：BACKGROUND:In men undergoing definitive radiation for prostate cancer, it is unclear whether early biochemical response can provide additional prognostic value beyond pre-treatment risk stratification. METHODS:Prostate cancer patients consecutively treated with definitive radiation at our institution by a single provi...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/pcan.2016.67

    authors： Narang AK,Trieu J,Radwan N,Ram A,Robertson SP,He P,Gergis C,Griffith E,Singh H,DeWeese TA,Honig S,Annadanam A,Greco S,DeVille C,McNutt T,DeWeese TL,Song DY,Tran PT

    更新日期：2017-06-01 00:00:00

  • Changes in prostate-specific antigen and hormone levels following withdrawal of prolonged androgen ablation for prostate cancer.

    abstract：:We conducted a study in order to characterize changes after withdrawal of androgen ablation (AA) for prostate cancer. AA was withdrawn in 38 Japanese patients with prostate cancer who had undergone this therapy for various periods. Patients were stratified into those who had undergone AA for less than 24 months (Group...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 临床试验,杂志文章

    doi：10.1038/sj.pcan.4500675

    authors： Egawa S,Okusa H,Matsumoto K,Suyama K,Baba S

    更新日期：2003-01-01 00:00:00

  • Magnetic resonance imaging in prostate cancer.

    abstract：:With the recently published National Institute of Clinical Excellence guidelines, it is now generally accepted that magnetic resonance imaging (MRI) is the imaging method of choice for staging prostate cancer in patients for whom radical treatment is being considered. MRI offers the single most accurate assessment of ...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章,评审

    doi：10.1038/sj.pcan.4500767

    authors： Heenan SD

    更新日期：2004-01-01 00:00:00

  • Imaging, procedural and clinical variables associated with tumor yield on bone biopsy in metastatic castration-resistant prostate cancer.

    abstract：BACKGROUND:Understanding the mechanisms driving disease progression is fundamental to identifying new therapeutic targets for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC). Owing to the prevalence of bone metastases in mCRPC, obtaining sufficient tumor tissue for analysis has histori...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/pcan.2014.28

    authors： McKay RR,Zukotynski KA,Werner L,Voznesensky O,Wu JS,Smith SE,Jiang Z,Melnick K,Yuan X,Kantoff PW,Montgomery B,Balk SP,Taplin ME

    更新日期：2014-12-01 00:00:00

  • Transcriptional profiling of transurethral resection samples provides insight into molecular mechanisms of hormone refractory prostate cancer.

    abstract：:The molecular mechanisms for hormone-resistant prostate cancer progression still remain elusive, mainly due to the limited availability of corresponding tissue. As transurethral resection (TUR) is a common palliative therapy for patients with hormone refractory prostate cancer (HRPC) who have subvesical obstruction, w...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/sj.pcan.4501001

    authors： Stoss O,Werther M,Zielinski D,Middel P,Jost N,Rüschoff J,Henkel T,Albers P

    更新日期：2008-01-01 00:00:00

  • Adjuvant and salvage treatment after radical prostatectomy: current practice in the UK.

    abstract：OBJECTIVE:To survey UK urologists and radiation oncologists in the evaluation and treatment of localised prostate cancer in the adjuvant and salvage setting. METHODS:Postal questionnaires were mailed to 292 urologists and 98 radiation oncologists in the UK. RESULTS:In all, 188 (48%) questionnaires were returned. In t...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/sj.pcan.4500816

    authors： Lee LW,Clarke NW,Ramani VA,Cowan RA,Wylie JP,Logue JP

    更新日期：2005-01-01 00:00:00

  • Diabetes and prostate cancer risk in the REDUCE trial.

    abstract：:Men with diabetes mellitus are less likely to be diagnosed with prostate cancer (PCa). As diabetic men have lower serum PSA, it is unclear if this is due to lower PCa incidence or reflects detection bias from fewer PSA-triggered biopsies. To account for differential biopsy rates, we used multivariate regression to exa...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/pcan.2011.28

    authors： Wu C,Moreira DM,Gerber L,Rittmaster RS,Andriole GL,Freedland SJ

    更新日期：2011-12-01 00:00:00

  • Evolution of multi-parametric MRI quantitative parameters following transrectal ultrasound-guided biopsy of the prostate.

    abstract：BACKGROUND:To determine the evolution of prostatic multi-parametric magnetic resonance imaging (mp-MRI) signal following transrectal ultrasound (TRUS)-guided biopsy. METHODS:Local ethical permission and informed written consent was obtained from all the participants (n=14, aged 43-69, mean 64 years). Patients with a c...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/pcan.2015.33

    authors： Latifoltojar A,Dikaios N,Ridout A,Moore C,Illing R,Kirkham A,Taylor S,Halligan S,Atkinson D,Allen C,Emberton M,Punwani S

    更新日期：2015-12-01 00:00:00

  • Association of diet and lifestyle with chronic prostatitis/chronic pelvic pain syndrome and pain severity: a case-control study.

    abstract：BACKGROUND:Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a common problem with unclear etiology. Some diet and lifestyle factors were thought to correlate with CP/CPPS, but studies comprehensively investigate this correlation are rarely available. The current study was conducted to determine the potenti...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/pcan.2015.57

    authors： Chen X,Hu C,Peng Y,Lu J,Yang NQ,Chen L,Zhang GQ,Tang LK,Dai JC

    更新日期：2016-03-01 00:00:00

  • BPH in the next millennium:a glimpse to the future.

    abstract：:Benign prostatic hyperplasia (BPH) is a highly prevalent, age-related disease. As the world population continues to grow and life expectancy increases, the population of men suffering from BPH will expand. A greater emphasis will be placed on quality of life. The BPH patient of the future will also have greater expect...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/sj.pcan.4500370

    authors： Gómez-Sancha F

    更新日期：1999-12-01 00:00:00

  • Validation of a genomic classifier for prediction of metastasis and prostate cancer-specific mortality in African-American men following radical prostatectomy in an equal access healthcare setting.

    abstract：BACKGROUND:The Decipher 22-gene genomic classifier (GC) may help in post-radical prostatectomy (RP) decision making given its superior prognostic performance over clinicopathologic variables alone. However, most studies evaluating the GC have had a modest representation of African-American men (AAM). We evaluated the G...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/s41391-019-0197-3

    authors： Howard LE,Zhang J,Fishbane N,Hoedt AM,Klaassen Z,Spratt DE,Vidal AC,Lin D,Hitchins MP,You S,Freeman MR,Yamoah K,Davicioni E,Freedland SJ

    更新日期：2020-09-01 00:00:00

  • Adiponectin inhibits oxidative stress in human prostate carcinoma cells.

    abstract：BACKGROUND:Emerging data suggest that obesity increases the risk of aggressive prostate cancer (PC), but the mechanisms underlying this relationship remain to be fully elucidated. Oxidative stress (OS) is a key process in the development and progression of PC. Adiponectin, an adipocyte-specific hormone, circulates at r...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/pcan.2011.53

    authors： Lu JP,Hou ZF,Duivenvoorden WC,Whelan K,Honig A,Pinthus JH

    更新日期：2012-03-01 00:00:00

  • Plasma cell-free DNA-based predictors of response to abiraterone acetate/prednisone and prognostic factors in metastatic castration-resistant prostate cancer.

    abstract：BACKGROUND:The combination of abiraterone acetate and prednisone (AA/P) is used to treat metastatic prostate cancer, but molecular predictors of treatment response are not well elucidated. We evaluated plasma circulating tumor DNA- (ctDNA-) based copy number alterations (CNAs) to determine treatment-related predictive ...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/s41391-020-0224-4

    authors： Du M,Tian Y,Tan W,Wang L,Wang L,Kilari D,Huang CC,Wang L,Kohli M

    更新日期：2020-12-01 00:00:00

  • Serum chromogranin-A-based prognosis in metastatic castration-resistant prostate cancer.

    abstract：OBJECTIVE:To determine the prognostic value of serum chromogranin-A (CGA) in a two-cohort study of men with metastatic castrate resistant prostate cancer (mCRPC) and to compare with circulating tumor cells (CTCs)-based prognosis. PATIENTS AND METHODS:A two-cohort-based evaluation for serum CGA for prognostication in C...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/s41391-018-0046-9

    authors： Giridhar KV,Sanhueza C,Hillman DW,Alkhateeb H,Carlson R,Tan W,Costello BA,Quevedo F,Pagliaro L,Kohli M

    更新日期：2018-09-01 00:00:00

  • Protective effect of pharmacological castration on metabolic perturbations and cardiovascular disease in the hyperglycemic male ApoE-/-:Ins2+/Akita mouse model.

    abstract：BACKGROUND:Unlike in other mouse models of atherogenesis, it has recently been suggested that orchiectomy plays a role in accelerating atherosclerosis and inhibiting the progression of cardiovascular disease in the ApoE-/-:Ins2+/Akita mouse model of hyperglycemia. Androgen-deprivation therapy (ADT) is a common treatmen...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/s41391-020-00288-y

    authors： Duivenvoorden WCM,Naeim M,Hopmans SN,Yousef S,Werstuck GH,Dason S,Pinthus JH

    更新日期：2020-09-28 00:00:00

  • Decipher correlation patterns post prostatectomy: initial experience from 2 342 prospective patients.

    abstract：BACKGROUND:Currently, there are multiple commercially available RNA-based biomarkers that are Medicare approved and suggested for use by the National Comprehensive Cancer Network guidelines. There is uncertainty as to which patients benefit from genomic testing and for whom these tests should be ordered. Here, we exami...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/pcan.2016.38

    authors： Den RB,Santiago-Jimenez M,Alter J,Schliekelman M,Wagner JR,Renzulli Ii JF,Lee DI,Brito CG,Monahan K,Gburek B,Kella N,Vallabhan G,Abdollah F,Trabulsi EJ,Lallas CD,Gomella LG,Woodlief TL,Haddad Z,Lam LL,Deheshi S,Wa

    更新日期：2016-12-01 00:00:00

  • Upregulation of erythropoietin receptor in human prostate carcinoma and high-grade prostatic intraepithelial neoplasia.

    abstract：:The aim of the present study was to investigate the differential expression of erythropoietin receptor (EPOR) in prostate carcinoma (PCa), high-grade prostatic intraepithelial neoplasia (PIN), prostatic hyperplasia (BPH) lesions and normal prostatic tissues by immunohistochemistry; and to test the hypothesis that upre...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/sj.pcan.4500995

    authors： Zhou T,Xu C,He M,Sun Y

    更新日期：2008-01-01 00:00:00

  • Predicting prostate cancer-specific outcome after radical prostatectomy among men with very high-risk cT3b/4 PCa: a multi-institutional outcome study of 266 patients.

    abstract：BACKGROUND:The value of radical prostatectomy (RP) as an approach for very high-risk prostate cancer (PCa) patients is controversial. To examine the risk of 10-year cancer-specific mortality (CSM) and other-cause mortality (OCM) according to clinical and pathological characteristics of very high-risk cT3b/4 PCa patient...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章,多中心研究

    doi：10.1038/pcan.2014.41

    authors： Moltzahn F,Karnes J,Gontero P,Kneitz B,Tombal B,Bader P,Briganti A,Montorsi F,Van Poppel H,Joniau S,Spahn M

    更新日期：2015-03-01 00:00:00

  • Cardiac biomarkers in patients with prostate cancer and cardiovascular disease receiving gonadotrophin releasing hormone agonist vs antagonist.

    abstract：BACKGROUND:Gonadotrophin releasing hormone (GnRH) agonists and antagonists reduce testosterone levels for the treatment of advanced and metastatic prostate cancer. Androgen deprivation therapy (ADT) is associated with increased risk of cardiovascular (CV) events and CV disease (CVD), especially in patients with preexis...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/s41391-020-0264-9

    authors： Margel D,Ber Y,Peer A,Shavit-Grievink L,Pinthus JH,Witberg G,Baniel J,Kedar D,Rosenbaum E

    更新日期：2020-07-31 00:00:00

  • Localized prostate cancer and 30 years of follow-up in a population-based setting.

    abstract：:Some patients with a histopathological diagnosis of prostate cancer have a tumour that behaves benignly during long-term follow-up. The proportion of patients with such a tumour is unknown, as is the fraction who die of prostate cancer between 10 and 20 y of follow-up. All men aged 45-84 y obtaining a diagnosis of pro...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/sj.pcan.4500395

    authors： Adolfsson J,Oksanen H,Salo JO,Steineck G

    更新日期：2000-07-01 00:00:00

  • High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features.

    abstract：:The role of neoadjuvant androgen deprivation (NAD) in high-risk prostate cancer patients receiving high-dose radiotherapy (RT) remains unstudied. To evaluate the effect of a course of NAD, we reviewed the experiences of three institutions treating these patients with combined RT and high-dose rate brachytherapy (HDR)....

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章,多中心研究

    doi：10.1038/sj.pcan.4500882

    authors： Vargas C,Martínez A,Galalae R,Demanes J,Harsolia A,Schour L,Nuernberg N,Gonzalez J

    更新日期：2006-01-01 00:00:00

  • Testosterone recovery in the off-treatment time in prostate cancer patients undergoing intermittent androgen deprivation therapy.

    abstract：BACKGROUND:Intermittent androgen deprivation (IAD) for prostate cancer was studied with the objective of reducing the side effects of treatment and potentially delaying the development of hormone resistance. There also appears to be a quality of life benefit during off-treatment intervals owing to the recovery of serum...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1038/pcan.2012.12

    authors： Tunn UW,Canepa G,Kochanowsky A,Kienle E

    更新日期：2012-09-01 00:00:00

  • Defining a role for the inhibitors of apoptosis proteins in prostate cancer.

    abstract：:The aim of this paper is to review the inhibitors of apoptosis proteins, a recently discovered group of caspase inhibitors. We will briefly review the relevance of apoptosis in prostate cancer and some of the control mechanisms, before describing the structure, function and regulation of these molecules. Lastly, we wi...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/sj.pcan.4500502

    authors： McEleny KR,Watson RW,Fitzpatrick JM

    更新日期：2001-01-01 00:00:00

  • The role of candidate genetic polymorphisms in the etiology of prostate cancer.

    abstract：:Prostate cancer appears to result from complex interactions among genetic, endocrine and environmental factors. Identification of risk factors for development and progression of prostate cancer is needed. This will allow researchers to design strategies to reduce the morbidity and mortality from this cancer and to ide...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/sj.pcan.4500471

    authors： Neuhausen SL

    更新日期：2000-12-01 00:00:00

  • The anticancer potential of metformin on prostate cancer.

    abstract：BACKGROUND:Prostate cancer (PCa) is characterized as the most frequent type of cancer in males. Recent research has suggested patients who have diabetes mellitus taking metformin (MF) have a lower risk of PCa. MF has antineoplastic effects such as adenosine monophosphate-activated protein kinase (AMPK)-dependent and in...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章,评审

    doi：10.1038/s41391-018-0085-2

    authors： Zaidi S,Gandhi J,Joshi G,Smith NL,Khan SA

    更新日期：2019-09-01 00:00:00

  • Prostate activity and prostate cancer in spinal cord injury.

    abstract：:In addition to androgen, autonomic nerves may be involved in prostatic function. As patients with spinal cord injury (SCI) have impaired innervation of the prostate, the prostate volume and prostate-specific antigen (PSA) level in patients with SCI may be different from those of healthy men. Experiments in rats with S...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章,评审

    doi：10.1038/sj.pcan.4500865

    authors： Shim HB,Jung TY,Lee JK,Ku JH

    更新日期：2006-01-01 00:00:00

  • Cost-effectiveness analysis of Abiraterone Acetate versus Docetaxel in the management of metastatic castration-sensitive prostate cancer: Hong Kong's perspective.

    abstract：BACKGROUND:Several randomized control trials (RCTs) have showed that adding either abiraterone acetate (AA) or docetaxel (D) to androgen-deprivation therapy (ADT) improves survival of metastatic castration-sensitive prostate cancer patients (mCSPC). Yet, the cost-effectiveness of these treatment options has not been fu...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/s41391-019-0161-2

    authors： Chiang CL,So TH,Lam TC,Choi HCW

    更新日期：2020-03-01 00:00:00

  • High level of dioxin-TEQ in tissue is associated with Agent Orange exposure but not with biochemical recurrence after radical prostatectomy.

    abstract：BACKGROUND:Agent Orange (AO) was previously identified as a significant risk factor for biochemical recurrence (BCR) after radical prostatectomy (RP) in prostate cancer patients. In this study, we determined the levels of dioxin biological toxicity using toxic equivalency (TEQ) values and examined the impact of dioxin-...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/pcan.2013.33

    authors： Li Q,Lan L,Klaassen Z,Shah SR,Moses KA,Terris MK

    更新日期：2013-12-01 00:00:00

  • Characterization of expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in prostate cancer cell lines.

    abstract：:Stromal expression of some matrix metalloproteinases (MMPs) has been associated with increasing tumour burden in prostate cancer. We investigated the expression of mRNA (by RT-PCR) and protein (by zymography and western blotting) of MMPs and endogenous inhibitors (tissue inhibitors of metalloproteinases, TIMPs) in two...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/sj.pcan.4500609

    authors： Daja MM,Niu X,Zhao Z,Brown JM,Russell PJ

    更新日期：2003-01-01 00:00:00